Anti-VEGF agents in the treatment of diabetic macular edema
Diabetic macular edema (DME) is a common complication associated with the loss of visual acuity in diabetic patients. Intravitreal injections of vascular endothelium growth factor (VEGF) inhibitors (anti-VEGF therapy) have been proposed recently as a new treatment option for patients with DME. In th...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2013-12-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/3871 |
| _version_ | 1797255213237665792 |
|---|---|
| author | Vladimir Iosifovich Konenkov Vadim Valerievich Klimontov Valeriy Vyacheslavovich Chernykh Nadezhda Viktorovna Tjan |
| author_facet | Vladimir Iosifovich Konenkov Vadim Valerievich Klimontov Valeriy Vyacheslavovich Chernykh Nadezhda Viktorovna Tjan |
| author_sort | Vladimir Iosifovich Konenkov |
| collection | DOAJ |
| description | Diabetic macular edema (DME) is a common complication associated with the loss of visual acuity in diabetic patients. Intravitreal injections of vascular endothelium growth factor (VEGF) inhibitors (anti-VEGF therapy) have been proposed recently as a new treatment option for patients with DME. In this review we summarized results of randomized clinical trials of VEGF inhibitors in DME patients. The results indicate that all studied inhibitors (ranibizumab, bevacizumab, pegaptanib and aflibersept) reduce the retinal thickness and improve of visual acuity in DME when are used as a monotherapy or in combination with the laser treatment. Optimal course duration and effectiveness predictors of anti-VEGF therapy in DME should be elucidate in the future studies. |
| first_indexed | 2024-03-08T15:21:22Z |
| format | Article |
| id | doaj.art-742d86e339d947eb8af79c385b38765a |
| institution | Directory Open Access Journal |
| issn | 2072-0351 2072-0378 |
| language | English |
| last_indexed | 2024-04-24T22:02:16Z |
| publishDate | 2013-12-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj.art-742d86e339d947eb8af79c385b38765a2024-03-20T11:47:58ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782013-12-01164788410.14341/DM2013478-843840Anti-VEGF agents in the treatment of diabetic macular edemaVladimir Iosifovich Konenkov0Vadim Valerievich Klimontov1Valeriy Vyacheslavovich Chernykh2Nadezhda Viktorovna Tjan3Research Institute of Clinical and Experimental Lymphology, NovosibirskResearch Institute of Clinical and Experimental Lymphology, NovosibirskNovosibirsk Branch of FSBI “The Acad. S.N. Fyodorov Eye Microsurgery Complex”, NovosibirskResearch Institute of Clinical and Experimental Lymphology, NovosibirskDiabetic macular edema (DME) is a common complication associated with the loss of visual acuity in diabetic patients. Intravitreal injections of vascular endothelium growth factor (VEGF) inhibitors (anti-VEGF therapy) have been proposed recently as a new treatment option for patients with DME. In this review we summarized results of randomized clinical trials of VEGF inhibitors in DME patients. The results indicate that all studied inhibitors (ranibizumab, bevacizumab, pegaptanib and aflibersept) reduce the retinal thickness and improve of visual acuity in DME when are used as a monotherapy or in combination with the laser treatment. Optimal course duration and effectiveness predictors of anti-VEGF therapy in DME should be elucidate in the future studies.https://www.dia-endojournals.ru/jour/article/view/3871diabetic macular edemavascular endothelium growth factorranibizumabbevacizumabpegaptanibafliberсept |
| spellingShingle | Vladimir Iosifovich Konenkov Vadim Valerievich Klimontov Valeriy Vyacheslavovich Chernykh Nadezhda Viktorovna Tjan Anti-VEGF agents in the treatment of diabetic macular edema Сахарный диабет diabetic macular edema vascular endothelium growth factor ranibizumab bevacizumab pegaptanib afliberсept |
| title | Anti-VEGF agents in the treatment of diabetic macular edema |
| title_full | Anti-VEGF agents in the treatment of diabetic macular edema |
| title_fullStr | Anti-VEGF agents in the treatment of diabetic macular edema |
| title_full_unstemmed | Anti-VEGF agents in the treatment of diabetic macular edema |
| title_short | Anti-VEGF agents in the treatment of diabetic macular edema |
| title_sort | anti vegf agents in the treatment of diabetic macular edema |
| topic | diabetic macular edema vascular endothelium growth factor ranibizumab bevacizumab pegaptanib afliberсept |
| url | https://www.dia-endojournals.ru/jour/article/view/3871 |
| work_keys_str_mv | AT vladimiriosifovichkonenkov antivegfagentsinthetreatmentofdiabeticmacularedema AT vadimvalerievichklimontov antivegfagentsinthetreatmentofdiabeticmacularedema AT valeriyvyacheslavovichchernykh antivegfagentsinthetreatmentofdiabeticmacularedema AT nadezhdaviktorovnatjan antivegfagentsinthetreatmentofdiabeticmacularedema |